Université catholique de Louvain

Defense Metals Appoints Guy de Selliers de Moranville to the Board of Directors

Retrieved on: 
星期三, 四月 3, 2024
Civil service commission, Organization, European Central Bank, Master, Reconstruction, Development finance institution, Knowledge, Norilsk Nickel, Metal, Université catholique de Louvain, Senior, Pulse, AG Insurance, European Commission, Lehman Brothers, World Bank, Defense, EBRD, Engineering, Economics, Solvay S.A., Mining, Management

VANCOUVER, BC, April 3, 2024 /PRNewswire/ - Defense Metals Corp. ("Defense Metals" or the "Company"; (TSXV: DEFN) (OTCQB: DFMTF) (FSE: 35D) is pleased to announce the appointment of Mr.

Key Points: 
  • VANCOUVER, BC, April 3, 2024 /PRNewswire/ - Defense Metals Corp. ("Defense Metals" or the "Company"; (TSXV: DEFN) (OTCQB: DFMTF) (FSE: 35D) is pleased to announce the appointment of Mr.
  • Guy de Selliers de Moranville as a new director to the Board of Directors.
  • "The entire Board and Management of Defense Metals are thrilled to welcome Guy, a seasoned business leader, as he helps steer us through the next phase of development at Wicheeda.
  • With Guy on board, Defense Metals gains the expertise of and knowledge of an experienced executive with a proven track record in corporate governance, finance and project development.

Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing

Retrieved on: 
星期四, 二月 29, 2024
AI, Research, TRAIL, Marche-en-Famenne, Database, Learning, Cell, Public service, Université catholique de Louvain, Partnership, Medical device

GERMANTOWN, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), today announced that the Company’s consortium was awarded a €2.0 million grant from the Walloon Government in Belgium, titled: “Monitoring with AI of Decentralized ATMP Manufacturing” (MAIDAM).

Key Points: 
  • GERMANTOWN, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), today announced that the Company’s consortium was awarded a €2.0 million grant from the Walloon Government in Belgium, titled: “Monitoring with AI of Decentralized ATMP Manufacturing” (MAIDAM).
  • The consortium members include: Orgenesis Services Belgium, Université catholique de Louvain (UCLouvain) / TRusted AI Labs (TRAIL) and DNAlytics.
  • The MAIDAM project is focused on developing AI-based approaches for the monitoring and improvement of decentralized manufacturing processes for ATMPs via federated machine and reinforcement learning utilizing cell therapy processing on small and standardized manufacturing units.
  • This project brings together a top-notch consortium with very complementary expertise in manufacturing of cell therapies, AI, and digitization of biomanufacturing processes.

PDC*line Pharma and Partners Receive €8.1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project

Retrieved on: 
星期三, 一月 17, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Retail, Genetics, Science, Clinical Trials, Université catholique de Louvain, Molecular imaging, Tumor microenvironment, OncoDNA, Patient, Neoplasm, HUB, DNA, Multimedia, Circulating tumor DNA, RNA, Liquid biopsy, Education minister, PDC, Cancer, Breast cancer, Institut Jules Bordet, B cell, Safety, ULB, CRC, Clinical trial, ATMP, Colorectal cancer, Pharmaceutical industry

PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancer, announces today the selection of the PDC*neo+ project for funding by the Walloon region and BioWin, the health cluster for Wallonia.

Key Points: 
  • PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancer, announces today the selection of the PDC*neo+ project for funding by the Walloon region and BioWin, the health cluster for Wallonia.
  • Members of the project consortium will receive €8.1M ($8.9M) in funding, including €4.7M ($5.1M) for PDC*line Pharma.
  • View the full release here: https://www.businesswire.com/news/home/20240117630349/en/
    The project aims to develop PDC*neo+, a personalized therapeutic vaccine for colorectal cancer using PDC*line Pharma's innovative PDC*line technology.
  • Globally, colorectal cancer (CRC) is among the most prevalent and deadly cancers , with a high recurrence rate post-surgery and chemotherapy.

Coave Therapeutics appoints Leading World Experts to newly formed Scientific Advisory Board dedicated to its Genetic Medicine Delivery Platform

Retrieved on: 
星期四, 十月 12, 2023
University of Pennsylvania, Knowledge, Doctor of Philosophy, Neuroscience, University of Massachusetts Chan Medical School, Education minister, CSO, Pediatrics, Stanford University School of Medicine, LDRI, Translational research, MD, Gene, United States Air Force Scientific Advisory Board, University, Duke University School of Medicine, Translation, Gene therapy, Université catholique de Louvain, Laboratory, AAV, Growth, Genetics, DSM-IV codes, DVM, LFCS, SAB, Patient, Vaccine, Management

Their collective expertise will also contribute to enhancing the ALIGATER™ platform and expanding its potential across viral (adeno-associated virus; AAV) and non-viral vector-based therapeutics, unlocking the potential to develop novel genetic medicines targeting serious diseases.

Key Points: 
  • Their collective expertise will also contribute to enhancing the ALIGATER™ platform and expanding its potential across viral (adeno-associated virus; AAV) and non-viral vector-based therapeutics, unlocking the potential to develop novel genetic medicines targeting serious diseases.
  • Lolita Petit, CSO of Coave Therapeutics commented, “We are absolutely thrilled to welcome our exceptional Scientific Advisory Board to the Coave team.
  • Each of these distinguished members has made profound contributions to the fields of genetic medicine, gene therapy, and neurosciences, bringing a unique depth of knowledge and experience to Coave.
  • We eagerly anticipate the opportunity to leverage their unique scientific insights to continue to advance our pipeline and ALIGATER platform.

Ready Education acquires European based company AppScho to drive Worldwide Student Success

Retrieved on: 
星期二, 十二月 14, 2021
ESSEC Business School, Sciences Po, Education, Founder CEO, Growth, École Polytechnique, Paris, Adoption, CEO, General manager, University, Internet, Sheffield Digital Campus, Faculty, HEC Paris, Software, Multimedia, Student, Université catholique de Louvain, Communication, View, Medicine, Tutoring, Management, Creative industries

Ready Education continues to execute its strategy of driving global student success in higher education by providing the leading Digital Campus experience and student success platform.

Key Points: 
  • Ready Education continues to execute its strategy of driving global student success in higher education by providing the leading Digital Campus experience and student success platform.
  • Earlier in 2021 Ready Education acquired Collabco, a UK-based company, and StuComm, a Netherlands-based company, both of which were leaders in student engagement software in their respective markets.
  • Their focus on student success accelerates our drive to offer the world's leading digital student communication, engagement and success platform and continues to benefit all of our stakeholders, including customers, partners, students and employees," said Gary Fortier, CEO of Ready Education.
  • Trusted by 425+ institutions to build communitiesand drive retention, Ready Education is the leading mobile student engagement platform on a mission to improve student success in higher education worldwide.

Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

Retrieved on: 
星期四, 十月 28, 2021
Safety, Series, Teaching hospital, Engineering, MD, VCS, Research, Technology, University, Entrepreneurship, CPT, MicroRNA, Université catholique de Louvain, UCL, Fracture, 3D, Regeneration, Patient, Ankle, FDA, Spinal fusion, EUR, List of life sciences, Tibia, Wallonia, Company, CUSL, Clinical trial, Board, Trial of the century, Physiology, Growth, CEO, NSV, IND, Foot, China Resources, Charoen Pokphand, International Classification of Functioning, Disability and Health, Doctor of Philosophy, Extracellular matrix, Pharmaceutical industry, Financial services, Medical imaging

In the near term Novadip is firmly focused on delivering further clinical evidence in support of its regenerative product platform.

Key Points: 
  • In the near term Novadip is firmly focused on delivering further clinical evidence in support of its regenerative product platform.
  • IND approval has been granted by the FDA allowing Novadip to conduct a pilot study with NVD-003 in the US.
  • This first close of the Series B financing takes the total amount of equity financing raised to date to EUR 58 million including the conversion of a EUR 11 million loan into Class B shares.
  • On top of that, Novadip has received recently non-dilutive public funding from the Walloon Region of EUR 13.4 million to support the Series B developments.

Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

Retrieved on: 
星期四, 十月 28, 2021
Safety, Series, Teaching hospital, Engineering, MD, VCS, Research, Technology, University, Entrepreneurship, CPT, MicroRNA, Université catholique de Louvain, UCL, Fracture, 3D, Regeneration, Patient, Ankle, FDA, Spinal fusion, EUR, List of life sciences, Tibia, Wallonia, Company, CUSL, Clinical trial, Board, Trial of the century, Physiology, Growth, CEO, NSV, IND, Foot, China Resources, Charoen Pokphand, International Classification of Functioning, Disability and Health, Doctor of Philosophy, Extracellular matrix, Pharmaceutical industry, Financial services, Medical imaging

In the near term Novadip is firmly focused on delivering further clinical evidence in support of its regenerative product platform.

Key Points: 
  • In the near term Novadip is firmly focused on delivering further clinical evidence in support of its regenerative product platform.
  • IND approval has been granted by the FDA allowing Novadip to conduct a pilot study with NVD-003 in the US.
  • This first close of the Series B financing takes the total amount of equity financing raised to date to EUR 58 million including the conversion of a EUR 11 million loan into Class B shares.
  • On top of that, Novadip has received recently non-dilutive public funding from the Walloon Region of EUR 13.4 million to support the Series B developments.

Telix In-Licences Novel Tumour Microenvironment PET Tracer

Retrieved on: 
星期四, 九月 9, 2021

The investigational-stage PET radiotracer, known as [18F]-3-fluoro-2-hydroxypropionate or [18F]-FLac, has demonstrated promise for imaging lactate metabolism in oxygenated tumours and tumour microenvironment (TME).

Key Points: 
  • The investigational-stage PET radiotracer, known as [18F]-3-fluoro-2-hydroxypropionate or [18F]-FLac, has demonstrated promise for imaging lactate metabolism in oxygenated tumours and tumour microenvironment (TME).
  • The most widely used commercial PET tracer today is 2-deoxy-2-[18F]-fluoro-D-glucose ([18F]-FDG), a radiolabelled glucose molecule that is used in ~90% of scans.
  • Imaging with [18F]-FDG PET is used to determine sites of abnormal glucose metabolism and can characterise and localise many tumour types.
  • Telix Chief Scientist, Dr. Michael Wheatcroft added, This is a very exciting and novel tumour tracer with the potential to complement the universal PET agent [18F]-FDG to improve the detection of all tumours.

Alvalux Awarded Second U.S. Patent Wearable Light Therapy Device for Eye Disease

Retrieved on: 
星期四, 四月 22, 2021
Catholic University of Leuven, Forestry education, Ottignies-Louvain-la-Neuve, Université catholique de Louvain

He added, "I would like to congratulate co-inventor Professor Denis Flandre ICTEAM institute at the Universit catholique de Louvain (UCLouvain) - for his contribution and shared vision to bring smart, small, wearable, home-therapy devices to people around the world.

Key Points: 
  • He added, "I would like to congratulate co-inventor Professor Denis Flandre ICTEAM institute at the Universit catholique de Louvain (UCLouvain) - for his contribution and shared vision to bring smart, small, wearable, home-therapy devices to people around the world.
  • First product CicaLux Energized Scar-Care is available for sale in the European Union, USA and other countries.
  • For more information visit www.cicalux.com and www.cicalux.us .\nAlvalux Medical is a Belgian based medical device company founded in 2015 by medtech veteran Michel Alvarez.
  • It aims to be a global leader in smart, wearable, energized, therapeutic devices for use at home, at work, or on the go.